Patients with severe chronic airways obstruction often respond poorly to inhaled salbutamol
in conventional dosage from a pressurized aerosol. We have investigated the response to …

Nine patients with severe chronic airway obstruction secondary to chronic bronchitis and
emphysema all preferred nebulised salbutamol solution to placebo in a double-blind …

Dose-response relationships for salbutamol were studied in eight patients suffering from
chronic airflow obstruction with no asthmatic features. Each inhaled, double blind, in …

Nineteen patients (12 men) mean age, 63.4 years (range, 32 to 78), with stable chronic
airflow limitation, mean FEV 1, 0.55 L (range, 0.3 to 1.05 L), completed an eight-week …

Breathlessness, exercise tolerance, and spirometry were measured in 12 patients whose
major symptom was breathlessness, secondary to severe chronic airflow limitation, during a …

High dose inhaled salbutamol is increasingly used in the management of chronic obstructive
airways disease. To determine the range of doses to achieve optimal bronchodilatation and …

In a double‐blind trial we have tested the effects of inhaling increasing doses of salbutamol
and terbutaline aerosol. In 12 patients with reversible airways obstruction we assessed the …

Two studies are presented, with the aim of establishing the dose potency ratio for salbutamol
given via Turbuhaler and via a pressurized metered-dose inhaler (pMDI). Both studies were …

The increasing use of air-driven nebulised bronchodilators by patients with airflow
obstruction has raised concern about the safety of this practice. We have investigated the …

A double blind, cross-over trial of the β 2-adrenergic stimulating drug, salbutamol, was
carried out in 16 volunteers. The drug (2 mg) or placebo was administered as 1 tablet 4 …